£769 Test Could Predict Breast Cancer Recurrence Up to 15 Years After Treatment
The £769 test uses artificial intelligence to give two recurrence risk scores and could help doctors target closer monitoring or more treatment.
4 Articles
4 Articles
£769 Test Could Predict Breast Cancer Recurrence Up to 15 Years After Treatment
Internewscast Internewscast A groundbreaking test designed to predict whether breast cancer may return after… This Post: £769 Test Could Predict Breast Cancer Recurrence Up to 15 Years After Treatment first appeared on Internewscast
AIM movers: Zanaga funding delays and Northern Bear share tender
EDX Medical (LON: EDX) has entered an agreement with Caris Life Sciences to make the Caris MI Clarity test that assesses short and long-term risk of breast cancer recurrence available in the UK. The share price increased 12.9% to 8.75p. Building services provider Northern Bear (LON: NTBR) is launching a tender offer of up to […] The post AIM movers: Zanaga funding delays and Northern Bear share tender appeared first on UK Investor Magazine.
EDX Medical Launches AI Breast Cancer Test In UK
EDX Medical Group has partnered with Caris Life Sciences to introduce the Caris MI Clarity test in the UK. The AI-powered diagnostic test assesses both early and long-term breast cancer recurrence risk, providing risk predictions covering up to 15 years for eligible postmenopausal patients.
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
